《大行》大摩升微軟(MSFT.US)目標價至530美元 生成式AI推動Azure增長加速
摩根士丹利發表報告,指根據新信息和對微軟(MSFT.US)最新假設更新分析,納入投資者反饋,並通過對資本支出隱含Azure AI收入的更新分析,對微軟目標價由482美元上調至530美元,相當於2027財年每股盈測17.71美元的30倍,確認「增持」評級。
該行指,雖然投資者繼續討論不斷增加資本支出的投資回報,但見到微軟在生成式AI投資上的回報越來越明顯,無論是直接變現化,還是推動更廣泛產品組合的IT市場份額增長方面。該行指,在即將推出生成式AI創新周期中的領先地位,結合穩健執行力,正推動Azure業務加速增長,費用控制支持該行對微軟每股盈利中雙位數年均複合增長率增長的預測。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.